Fondazione IRCCS Istituto Nazionale Dei Tumori

26 trials 16 recruiting Academic / non-commercial

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

16 Recruiting

5 Completed trials

1 Countries active

40 Unique IMPs

100% Results reported

Phase II

Phase III: 2 Phase II: 21 Phase IV: 1 Phase I (FiH): 2

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Mantle cell lymphoma refractory 1 Adult T-cell lymphoma/leukaemia 1 Brain stem glioma 1 Mantle cell lymphoma recurrent 1 Triple negative breast cancer 1 Bladder cancer 1 Pseudomyxoma peritonei 1 Adult T-cell lymphoma/leukaemia refractory 1 Mantle cell lymphoma 1 Ovarian cancer 1 Adult T-cell lymphoma/leukaemia recurrent 1 Clear cell renal cell carcinoma 1

Top IMPs

PEMBROLIZUMAB 5 ACETYLSALICYLIC ACID 3 CARBOPLATIN 3 CISPLATIN 3 DEXAMETHASONE PHOSPHATE 2 DURVALUMAB 2 ETOPOSIDE 2 KETOROLAC TROMETAMOL 2 METFORMIN HYDROCHLORIDE 2 PACLITAXEL 2 ATEZOLIZUMAB 1 BREXUCABTAGENE AUTOLEUCEL 1

All trials — page 2

26 total

Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiothera… Ended

2024-513654-30-00 Phase II 1 country VINORELBINE TARTRATE
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon… Expired

2022-502907-31-00 Phase II 1 country BREXUCABTAGENE AUTOLEUCEL; IBRUTINIB

Showing 25–26 of 26 trials

← All sponsors A–Z